Axsome Therapeutics, Inc

Newest shelf

No limit

S-3ASR of 2025-11-03. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

At the market

$250.0M

Leerink Partners, agreement of 2022-03-01. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

28K

Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $74.75. 10-Q ↗

Cash

18 quarters

$319.9M on 2026-06-30 ÷ $17.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗